Preferences help
enabled [disable] Abstract
Number of results
2018 | 102 | 30-46
Article title

Current clinical management of malignant melanoma – diagnosis process and innovative therapies

Title variants
Languages of publication
Malignant melanoma is a highly invasive cancer which derives from neuroectodermic melanocytic cells. It is characterized by the highest frequency of cases in both sexes and all age groups. High metastatic potential of melanoma and its multidrug resistance might be a significant problem in the treatment. Permanent and complete remissions are rare, while the 5-year survival rate remains relatively low. In the last years there has been a breakthrough in the systemic therapy of malignant melanoma. Modern drugs have revolutionized previous therapeutic management of melanoma. As part of therapeutic programs, new medicines are available: dabrafenib, ipilimumab, pembrolizumab, trametinib and vemurafenib. The following paper presents current clinical management standards for melanoma diagnoses, based on the widely accepted scientific data and expert experience - with emphasis on modern methods of treatment of this cancer.
Physical description
  • Faculty of Medicine, Wroclaw Medical University, 5, J. Mikulicza-Radeckiego Str., 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, 5, J. Mikulicza-Radeckiego Str., 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, 5, J. Mikulicza-Radeckiego Str., 50-345 Wroclaw, Poland
  • Faculty of Medicine, Wroclaw Medical University, 5, J. Mikulicza-Radeckiego Str., 50-345 Wroclaw, Poland
  • Department of Medical Biochemistry, Wroclaw Medical University, 10, Chalubinskiego Str., 50-368, Wroclaw, Poland
  • Department of Medical Biochemistry, Wroclaw Medical University, 10, Chalubinskiego Str., 50-368, Wroclaw, Poland
  • [1] Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev. Anticancer Ther. 10(11) (2010) 1811–23.
  • [2] Krajowy Rejestr Nowotworów, Dane Statystyczne - Czerniak skóry (C43). [Online]. Available: [Accessed: 01-Apr-2018].
  • [3] Iams WT, Sosman JA, Chandra S. Novel Targeted Therapies for Metastatic Melanoma. Cancer J. 23(1) (2017) 54–58.
  • [4] Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 22(20) (2003) 3042–3052.
  • [5] Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin. Proc. 87(10) (2012) 991–1003.
  • [6] Bommer UA, Vine KL, Bommer U. Cancer biology: molecular and genetic basis "Chapter 3 -Cancer Biology: Molecular and Genetic Basis.”
  • [7] Drewa G, Powierska-Czarny J. Genetic basis of malignant melanoma. Postepy Hig. Med. Dosw. vol. 52(4) (1998) 367–80.
  • [8] Eckerle Mize D, Bishop M, Resse E, Sluzevich J. Familial Atypical Multiple Mole Melanoma Syndrome. National Center for Biotechnology Information (US), 2009.
  • [9] Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, Boiocchi C. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. cancer 74(1) (1997) 26–30.
  • [10] Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10 (2012) 85.
  • [11] Weiss J, Heine M, Arden KC, Korner B, Pilch H, Herbst RA, Jung EG. Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res. 139 (1995) 137–54.
  • [12] Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28(6) (2014) 1005–11.
  • [13] Czajkowski R, Placek W, Drewa G, Czajkowska A, Uchańska G. FAMMM syndrome: pathogenesis and management. Dermatol. Surg. 30(2) (2004) 291–6.
  • [14] Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic Carcinoma Surveillance in Patients With Familial Melanoma. Arch. Dermatol. 139(8) (2003) 1019.
  • [15] Vyas R, Selph J, Gerstenblith MR. Cutaneous manifestations associated with melanoma. Semin. Oncol. 43(3) (2016) 384–389.
  • [16] Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW, Polsky D. Early Diagnosis of Cutaneous Melanoma. JAMA 292(22) (2004) 2771.
  • [17] Daniel Jensen J, Elewski BE. The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations. J. Clin. Aesthet. Dermatol. 8(2) (2015) 15.
  • [18] Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev. Dermatol. 3(5) (2008) 569–585.
  • [19] Situm M, Buljan M, Kolić M, Vučić M. Melanoma - clinical, dermatoscopical, and histopathological morphological characteristics. Acta Dermatovenerol. Croat. 22(1) (2014) 1–12.
  • [20] Krathen M. Malignant Melanoma: Advances in Diagnosis, Prognosis, and Treatment. Semin. Cutan. Med. Surg. 31(1) (2012) 45–49.
  • [21] Beasley GM, Hu Y, Youngwirth L, Scheri RP, Salama AK, Rossfeld K, Gardezi S, Agnese DM, Howard JH, Tyler DS, Slingluff CL Jr, Terando AM. Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. Ann. Surg. Oncol. 24(8) (2017) 2728–2733.
  • [22] Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA. Cancer J. Clin. 67(2) (2017) 93–99.
  • [23] Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA. Cancer J. Clin. 67(6) (2017) 472–492.
  • [24] Danialan R, Gopinath A, Phelps A, Murphy M, Grant-Kels JM. Accurate identification of melanoma tumor margins: a review of the literature. Expert Rev. Dermatol. 7(4) (2012) 343–358.
  • [25] Riker AI, Kirksey L, Thompson L, Morris A, Cruse CW. Current surgical management of melanoma. Expert Rev. Anticancer Ther. 6(11) (2006) 1569–83.
  • [26] McCarter MD. "Melanoma” in Abernathy’s Surgical Secrets. Elsevier, (2009) 328–335.
  • [27] Mun GH. Management of malignant melanoma. Arch. Plast. Surg. 39(5) (2012) 565–74.
  • [28] Bigi L, Galdo G, Cesinaro AM, Vaschieri C, Marconi A, Pincelli C, Fantini F. Electrochemotherapy induces apoptotic death in melanoma metastases: a histologic and immunohistochemical investigation. Clin. Cosmet. Investig. Dermatol. 9 (2016) 451–459.
  • [29] Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J. Am. Coll. Surg. 213(2) (2011) 306–16.
  • [30] Davar D, Kirkwood JM. Adjuvant Therapy of Melanoma. Cancer treatment and research 167 (2016) 181–208.
  • [31] Song X, Zhao Z, Barber B, Farr AM, Ivanov B, Novich M. Overall survival in patients with metastatic melanoma. Curr. Med. Res. Opin. 31(5) (2015) 987–991.
  • [32] Ugurel S, Paschen A, Becker JC. Dacarbazine in Melanoma: From a Chemotherapeutic Drug to an Immunomodulating Agent. J. Invest. Dermatol. 133(2) (2013) 289–292.
  • [33] Petrella T, Quirt I, Verma S, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat. Rev. 33(5) (2007) 484–96.
  • [34] Jason F, Luke J. Is There an Optimal Dose of Ipilimumab in Melanoma? ASCO Annual Meeting. ASCO Daily News, 2017.
  • [35] Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother. Radiopharm. 25(6) (2010) 601–13.
  • [36] Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 17(22) (2011) 6958–62.
  • [37] McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol. Cell Biol. 77(1) (1999) 1.
  • [38] Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25(21) (2005) 9543–53.
  • [39] Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. 4(5) (2015) 661–72.
  • [40] Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, Machet L. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br. J. Dermatol. 174(1) (2016) 146–151.
  • [41] Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J. Clin. Oncol. 33(17) (2015) 1889–1894.
  • [42] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372(26) (2015) 2521–2532.
  • [43] Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J. Immunother. Cancer. 3(1) (2015) 36.
  • [44] Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib. Drugs 72(17) (2012) 2207–2222.
  • [45] Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br. J. Cancer 114(7) (2016) 801–8.
  • [46] Knapen LM, Koornstra RHT, Driessen JHM, et al. The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Target. Oncol. Apr. 2018.
  • [47] Zecena H, Tveit D, Wang Z, et al. Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. BMC Syst. Biol. 12(1) (2018) 33.
  • [48] Fisher R, Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag. Res. 4 (2012) 243–52.
  • [49] Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol. 1(3) (2015) 380.
  • [50] Telang S, O'Neal J, Tapolsky G, Clem B, Kerr A, Imbert-Ferndandez Y, Chesney J. Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2(1) (2014) P14.
  • [51] Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839) (2012) 358–365.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.